Translational Orphan Blood Cancer Research Initiative
The UVA Comprehensive Cancer Center’s Translational Orphan Blood Cancer Research Initiative (TOBCRI) pursues new treatments for blood cancers so rare they are designated “orphan” diseases and have historically received limited research scrutiny and funding. TOBCRI is an interdisciplinary, donor-supported and project-based effort that collaborates with partner institutions under the direction of two leading researchers: Owen A. O’Connor, MD, PhD, UVA’s American Cancer Society Research Professor, who invented and developed multiple blood cancer drugs, and Thomas Loughran, MD, PhD, the Director of UVACCC, the discoverer of LGL leukemia.
Meet TOBCRI’s leadership, principal investigators, oversight team and program affiliates.
Learn about TOBCRI’s work to create the next generation of therapies for rare blood cancers.
Working to bring together researchers and patients to fight rare blood cancers.